

DAFTAR PUSTAKA

1. Dubey, JP. The history of *Toxoplasma gondii*--the first 100 years. J Eukaryot Microbiol. 2008;55(6):467-75.
2. Pappas G, Roussos N, Falagas ME. Toxoplasmosis snapshots: global status of *Toxoplasma gondii* seroprevalence and implications for pregnancy and congenital toxoplasmosis. Int J Parasitol. 2009;39(12):1385-94.
3. El Deeb HK, Salah-Eldin H, Khodeer S, Allah AA. Prevalence of *Toxoplasma gondii* infection in antenatal population in Menoufia governorate, Egypt. Acta Trop. 2012;124(3):185-91.
4. Aditama N, Nurjazuli, Dina RA. Determinan lingkungan dan perilaku berhubungan dengan terjadinya penyakit infeksi toxoplasmosis di wilayah Kota Semarang. Jurnal Kesehatan Masyarakat. 2016;4(5):2356-3346.
5. Soedarto. Toksoplasmosis, mencegah dan mengatasi penyakit melindungi ibu dan anak. Jakarta: Sagung Seto; 2012.
6. Nasrul, EY. Gambaran *Toxoplasma gondii* pada feses kucing di Kecamatan Padang Utara Kota Padang (skripsi). Fakultas Kedokteran Universitas Andalas. 2015:3.
7. Abdoli A, Barati M, Dalimi A, Pirestani M, Hoseini Shokouh SJ. Toxoplasmosis among patients with immunocompromising conditions: A snapshot. J Arch Mil Med. 2016;4(4):e41832.
8. Wang ZD, Liu HH, Ma ZX, Ma HY, Li ZY, Yang ZB, et al. *Toxoplasma gondii* infection in immunocompromised patients: A systematic review and meta-analysis. Front Microbiol. 2017;8:389.
9. Liu L, Wang P, Xu J, Xia CM. Increased risk of *Toxoplasma gondii* infection in cancer patients: A meta-analysis of current evidence based on case-control study. Acta Trop. 2019;192:30-40.
10. Ali MI, Abd El Wahab WM, Hamdy DA, Hassan A. *Toxoplasma gondii* in cancer patients receiving chemotherapy: seroprevalence and interferon gamma level. J Parasit Dis. 2019;43(3):464-71.

11. Goldszmid RS, Dzutsev A, Trinchieri G. Host immune response to infection and cancer: unexpected commonalities. *Cell Host Microbe*. 2014;15(3):295-305.
12. Anvari D, Sharif M, Sarvi S, Aghayan SA, Gholami S, Pagheh AS, *et al*. Seroprevalence of *Toxoplasma gondii* infection in cancer patients: A systematic review and meta-analysis. *Microb Pathog*. 2019;129:30-42.
13. Cong W, Liu GH, Meng QF, Dong W, Qin SY, Zhang FK, *et al*. *Toxoplasma gondii* infection in cancer patients: prevalence, risk factors, genotypes and association with clinical diagnosis. *Cancer Lett*. 2015;359(2):307-13.
14. Bajnok J, Tarabulsi M, Carlin H, Bown K, Southworth T, Dungwa J, *et al*. High frequency of infection of lung cancer patients with the parasite *Toxoplasma gondii*. *ERJ Open Res*. 2019;5(2):00143-2018.
15. Yazar S, Yaman O, Eser B, Altuntas F, Kurnaz F, Sahin I. Investigation of anti-*Toxoplasma gondii* antibodies in patients with neoplasia. *J Med Microbiol*. 2004;53(Pt 12):1183-6.
16. Alim M, Özçelik S, Özpinar N. Seroprevalence of *Toxoplasma gondii* in patients receiving cancer treatment. *Cumhuriyet Med J*. 2018;40(1):19-24.
17. Rai SK, Upadhyay MP, Shrestha HG. *Toxoplasma* infection in selected patients in Kathmandu, Nepal. *Nepal Med Coll J*. 2003;5(2):89-91.
18. Shin DW, Cha DY, Hua QJ, Cha GH, Lee YH. Seroprevalence of *Toxoplasma gondii* infection and characteristics of seropositive patients in general hospitals in Daejeon, Korea. *Korean J Parasitol*. 2009;47(2):125-30.
19. Robert-Gangneux F, Dardé ML. Epidemiology of and diagnostic strategies for toxoplasmosis. *Clin Microbiol Rev*. 2012;25(2):264-96.
20. Silva-Gutierrez N, Bahsas Zaky R, Bouchard M, Teran Angel G, Amoroso A, Peterson DL, *et al*. T-cell profiles elicited by *Toxoplasma gondii* in acutely/chronically infected humans. *Parasite Immunol*. 2018;40(6):e12532.
21. Aguirre AA, Longcore T, Barbieri M, Dabritz H, Hill D, Klein PN, *et al*. The one health approach to toxoplasmosis: epidemiology, control, and prevention strategies. *Ecohealth*. 2019;16(2):378-90.
22. Dubey JP. Advances in the life cycle of *Toxoplasma gondii*. *Int J Parasitol*. 1998;28(7):1019-24.

23. Berdoy M, Webster JP, Macdonald DW. Fatal attraction in rats infected with *Toxoplasma gondii*. Proc Biol Sci. 2000; 267(1452): 1591-94.
24. Vyas A, Kim SK, Giacomini N, Boothroyd JC, Sapolsky RM. Behavioral changes induced by *Toxoplasma* infection of rodents are highly specific to aversion of cat odors. Proc Natl Acad Sci U S A. 2007;104(15):6442-7.
25. Dubey JP. History of the discovery of the life cycle of *Toxoplasma gondii*. Int J Parasitol. 2009;39(8):877-82.
26. Mordue DG, Hakansson S, Niesman I, Sibley LD. *Toxoplasma gondii* resides in a vacuole that avoids fusion with host cell endocytic and exocytic vesicular trafficking pathways. Exp Parasitol. 1999;92(2):87-99.
27. Zhang YW, Halonen SK, Ma YF, Wittner M, Weiss LM. Initial characterization of CST1, a *Toxoplasma gondii* cyst wall glycoprotein. Infect Immun. 2001;69(1):501-7.
28. Lilue J, Müller UB, Steinfeldt T, Howard JC. Reciprocal virulence and resistance polymorphism in the relationship between *Toxoplasma gondii* and the house mouse. Elife. 2013 Oct 29;2:e01298.
29. Dubey JP, Lindsay DS, Speer CA. Structures of *Toxoplasma gondii* tachyzoites, bradyzoites, and sporozoites and biology and development of tissue cysts. Clin Microbiol Rev. 1998;11(2):267-99.
30. Bamba S, Cissé M, Sangaré I, Zida A, Ouattara S, Guiguemdé RT. Seroprevalence and risk factors of *Toxoplasma gondii* infection in pregnant women from Bobo Dioulasso, Burkina Faso. BMC Infect Dis. 2017;17:482.
31. Retmanasari A, Widartono BS, Wijayanti MA, Artama WT. Prevalence and risk factors for toxoplasmosis in Middle Java, Indonesia. Ecohealth. 2017;14(1):162-70.
32. Teweldemedhin M, Gebremichael A, Geberkirstos G, Hadush H, Gebrewahid T, Asgedom SW, et al. Seroprevalence and risk factors of *Toxoplasma gondii* among pregnant women in Adwa district, northern Ethiopia. BMC Infect Dis. 2019;19(1):327.
33. Iddawela D, Vithana SMP, Ratnayake C. Seroprevalence of toxoplasmosis and risk factors of *Toxoplasma gondii* infection among pregnant women in Sri Lanka: a cross sectional study. BMC Public Health. 2017;17(1):930.

34. Frimpong C, Makasa M, Sitali L, Michelo C. Seroprevalence and determinants of toxoplasmosis in pregnant women attending antenatal clinic at the university teaching hospital, Lusaka, Zambia. *BMC Infect Dis.* 2017;17(1):10.
35. Iskandar C. Patogenesis toksoplasmosis (thesis). Fakultas Kedokteran Universitas Kristen Maranatha. 2005.
36. Furtado JM, Smith JR, Belfort R Jr, Gattey D, Winthrop KL. Toxoplasmosis: a global threat. *J Glob Infect Dis.* 2011;3(3):281-4.
37. Halonen SK, Weiss LM. Toxoplasmosis. *Handb Clin Neurol.* 2013;114:125-45.
38. Montoya JG, Remington JS. Management of *Toxoplasma gondii* infection during pregnancy. *Clin Infect Dis.* 2008;47(4):554-66.
39. Montoya JG, Liesenfeld O. Toxoplasmosis. *Lancet.* 2004;363(9425):1965-76.
40. Iskandar A, Mayashinta DK, Sudjari, Indra MR. 1st ed. Mengenal *Toxoplasma gondii*, obesitas dan sindrom metabolik. Malang: UB Press; 2018:15.
41. Wallon M, Cozon G, Ecochard R, *et al.* Serological rebound in congenital toxoplasmosis: long-term followup of 133 children. *Eur J Pediatr.* 2001;160:534-40.
42. Jones LA, Alexander J, Roberts CW. Ocular toxoplasmosis: in the storm of the eye. *Parasite Immunol.* 2006;28(12):635-42.
43. Vallochi AL, Nakamura MV, Schlesinger D, *et al.* Ocular toxoplasmosis: more than just what meets the eye. *Scand J Immunol.* 2002;55(4):324-8.
44. Bosch-Driessen LH, Karimi S, Stilma JS, Rothova A. Retinal detachment in ocular toxoplasmosis. *Ophthalmology.* 2000;107(1):36-40.
45. Eckert GU, Melamed J, Menegaz B. Optic nerve changes in ocular toxoplasmosis. *Eye (Lond).* 2007;21(6):746-51.
46. Pereira-Chiocola VL, Vidal JE, Su C. *Toxoplasma gondii* infection and cerebral toxoplasmosis in HIV-infected patients. *Future Microbiol.* 2009;4(10):1363-79.
47. Chaudhry SA, Gad N, Koren G. Toxoplasmosis and pregnancy. *Can Fam Physician.* 2014;60(4):334-6.

48. Soedarto. Masalah titer IgG dan IgM dalam menentukan diagnosis toksoplasmosis. Jurnal Ilmiah Kedokteran Wijaya Kusuma. 2017;(2):1-5.
49. Institute for Quality and Efficiency in Health Care. The innate and adaptive immune system. Germany: Cologne. 2016.
50. Solomayer EF, Feuerer M, Bai L, Umansky V, Beckhove P, Meyberg GC, *et al*. Influence of adjuvant hormone therapy and chemotherapy on the immune system analysed in the bone marrow of patients with breast cancer. Clin Cancer Res. 2003;9(1):174-80.
51. Li Y. T-cell immune suppression in patients with hematologic malignancies: clinical implications. Int J Hematol Oncol. 2014;3(4):289-97.
52. Abdel Malek R, Wassef R, Rizk E, Sabry H, Tadros N, Boghdady A. Toxoplasmosis an overlooked disease: seroprevalence in cancer patients. Asian Pac J Cancer Prev. 2018;19(7):1987-91.
53. Baiomy AM, Mohamed KA, Ghannam MA, Shahat SA, Al-Saadawy AS. Opportunistic parasitic infections among immunocompromised Egyptian patients. J Egypt Soc Parasitol. 2010;40(3):797-808.
54. Israelski DM, Remington JS. Toxoplasmosis in patients with cancer. Clin Infect Dis. 1993;17(Suppl 2):S423-35.
55. Adiwijono. Teknik-teknik pemberian kemoterapi. In: Sudoyo AW, Setiyohadi B, editors. Buku ajar ilmu penyakit dalam jilid 2. Jakarta: Pusat Penerbitan Ilmu Penyakit Dalam Fakultas Kedokteran Universitas Indonesia. 2006.p855-65.
56. Departemen Obstetri dan Ginekologi Fakultas Kedokteran Universitas Padjajaran. Prinsip dasar kemoterapi. Bandung: Sagung Seto. 2013.
57. Ariawati K, Windiastuti E, Gatot D. Toksisitas kemoterapi leukemia limfoblastik akut pada fase induksi & profilaksis susunan saraf pusat dengan metotreksat 1 gram. Sari Pediatri. 2007;9(4):252-8.
58. American Cancer Society (2017). Low white blood cell (neutrophil) count and the risk of infection. The American Cancer Society. <http://www.cancer.org/treatment/treatments-and-side-effects/physical-side-effects/low-blood-counts/infections/infections-in-people-with-cancer/low-wbc-and-weak-immune-system.html> - Diakses Februari 2020.

59. Sibley LD. Invasion and intracellular survival by protozoan parasites. *Immunol Rev.* 2011;240(1):72-91.
60. Lim DC, Cooke BM, Doerig C, Saeij JP. Toxoplasma and Plasmodium protein kinases: Roles in invasion and host cell remodelling. *Int J Parasitol.* 2012;42(1):21-32.
61. Cesbron-Delauw MF, Gendrin C, Travier L, Ruffiot P, Mercier C. Apicomplexa in mammalian cells: trafficking to the parasitophorous vacuole. *Traffic.* 2008;9(5):657-64.
62. Baldursson S, Karanis P. Waterborne transmission of protozoan parasites: review of worldwide outbreaks-an update 2004-2010. *Water Res.* 2011;45(20):6603-14.
63. Meireles LR, Ekman CCJ, de Andrade HF. Jr, Luna EJ. Human toxoplasmosis outbreaks and the agent infecting form. Findings from a systematic review. *Rev Inst Med Trop Sao Paulo.* 2015;57(5):369-76.
64. Ahmed DF, Saheb EJ. Prevalence of Toxoplasmosis Infection in Iraqi Women with Different Types of Cancer. *Diyala Journal of Medicine.* 2017;13(2):56-62.
65. Bachireddy P, Burkhardt UE, Rajasagi M, Wu CJ. Hematologic malignancies: at the forefront of immunotherapeutic innovation. *Nat Rev Cancer.* 2015;15(4):201-15.
66. Zhou N, Fu H, Wang Z, Shi H, Yu Y, Qu T, *et al.* Seroprevalence and risk factors of *Toxoplasma gondii* infection in children with leukemia in Shandong Province, Eastern China: a case-control prospective study. *PeerJ.* 2019;7:e6604.
67. Harker KS, Ueno N, Lodoen MB. *Toxoplasma gondii* dissemination: a parasite's journey through the infected host. *Parasite Immunol.* 2015;37(30):141-9.
68. Alvarado-Esquivel C, Sánche-Anguiano LF, Hernández-Tinoco J, Ramos Nevarez A, Estrada-Martínez S, Cerrillo-Soto SM, *et al.* Association between *Toxoplasma gondii* infection and history of blood transfusion: a case-control seroprevalence study. *J Int Med Res.* 2018;46(4):1626-33.

69. Sasai M, Pradipta A, Yamamoto M. Host immune responses to *Toxoplasma gondii*. *Int Immunol*. 2018;30(3):113-119.
70. Barragan A, Sibley LD. Transepithelial migration of *Toxoplasma gondii* is linked to parasite motility and virulence. *J Exp Med*. 2002;195:1625-33.
71. Gazzinelli RT, Hieny S, Wynn TA, Wolf S, Sher A. Interleukin 12 is required for the T lymphocyte-independent induction of interferon gamma by an intracellular parasite and induces resistance in T-cell-deficient hosts. *Proc Natl Acad Sci U S A*. 1993;90(13):6115-19.
72. Gazzinelli RT, Wysocka M, Hayashi S, Denkers EY, Hieny S, Caspar P, Trinchieri G, Sher A. Parasite-induced IL-12 stimulates early IFN-gamma synthesis and resistance during acute infection with *Toxoplasma gondii*. *J Immunol*. 1994;153(6):2533-43.
73. Hunter CA, Subauste CS, Van Cleave VH, Remington JS. Production of gamma interferon by natural killer cells from *Toxoplasma gondii*-infected SCID mice: regulation by interleukin-10, interleukin-12, and tumor necrosis factor alpha. *Infect Immun*. 1994;62(7):2818-24.
74. Suzuki Y, Orellana MA, Schreiber RD, Remington JS. Interferon-gamma: the major mediator of resistance against *Toxoplasma gondii*. *Science*. 1988;240(4851):516-18.
75. Tosh KW, Mittereder L, Bonne-Annee S, Hieny S, Nutman TB, Singer SM, *et al*. The IL-12 Response of Primary Human Dendritic Cells and Monocytes to *Toxoplasma gondii* Is Stimulated by Phagocytosis of Live Parasites Rather Than Host Cell Invasion. *J Immunol*. 2016;196(1):345-56.
76. Dupont CD, Christian DA, Hunter CA. Immune response and immunopathology during toxoplasmosis. *Semin Immunopathol*. 2012;34(6):793–813.
77. American Cancer Society (2015). Poor nutrition can affect infection risk in people with cancer. The American Cancer Society. <http://www.cancer.org/treatment/treatments-and-side-effects/physical-side-effects/low-blood-counts/infections/infections-in-people-with-cancer/low-wbc-and-weak-immune-system.html> - Diakses Februari 2020.